Elan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*
Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer
Elan Announces Transactions: Decisively Transforming the Company
We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.
An examination of 10 CEFs with the highest duration risk.